NEO NEOGENOMICS INC
Services-Testing Laboratories · Nasdaq · SEC CIK 1077183 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.1%
TTM net income YoY71.5%
TTM EPS YoY71.6%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—
Margins
Gross margin44.8%
Operating margin-6.3%
Net margin-4.1%
FCF margin-3.6%
EBITDA margin-1.9%
Returns
ROE-3.9%
ROA-2.3%
ROIC (approx.)-4.6%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets41.9%
Debt / equity0.47x
Current ratio3.53x
Interest coverage-15.21x
Cash quality & payout
Operating cash flow / net income-0.13x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $727.33M | $660.57M |
| Cost of revenue | $413.04M | $370.47M |
| Gross profit | $314.29M | $290.10M |
| R&D expense | $37.08M | $31.16M |
| SG&A expense | $273.34M | $259.74M |
| Operating income | -$115.88M | -$92.11M |
| Interest expense | $3.75M | $6.62M |
| Pretax income | -$110.27M | -$80.67M |
| Income tax | -$2.24M | -$1.95M |
| Net income | -$108.03M | -$78.73M |
| EBITDA | -$79.81M | -$53.01M |
| EPS (diluted) | — | — |
| Weighted avg. shares (diluted) | 128.10M | 126.66M |
| Balance sheet | ||
| Cash & equivalents | $159.62M | $367.01M |
| Receivables | $159.24M | $150.54M |
| Inventory | $28.57M | $26.75M |
| Current assets | $376.29M | $596.02M |
| PP&E, net | $84.83M | $94.10M |
| Goodwill | $524.34M | $522.77M |
| Intangibles | $286.53M | $339.68M |
| Total assets | $1.36B | $1.64B |
| Current liabilities | $88.30M | $301.24M |
| Short-term debt | $0 | $200.78M |
| Long-term debt | $341.86M | $340.33M |
| Total debt | $341.86M | $541.11M |
| Total liabilities | $523.27M | $735.70M |
| Shareholders' equity | $836.56M | $902.34M |
| Net debt | $182.24M | $174.10M |
| Shares outstanding | 128.99M | 128.15M |
| Cash flow statement | ||
| Operating cash flow | $5.23M | $7.02M |
| Capital expenditure | $27.01M | $41.06M |
| Free cash flow | -$21.78M | -$34.04M |
| Investing cash flow | -$12.34M | $12.86M |
| Financing cash flow | -$200.29M | $4.65M |
| Depreciation & amortization | $36.07M | $39.10M |
| Stock-based compensation | $41.32M | $33.41M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.